National Cancer Policy Summit

When: October 25, 2010 (7:30 AM Eastern)
Where: St. Gregory Hotel & Suites (Ballroom) • 2033 M Street, NW, Washington, DC 20036

Topics Biomedical and Health Research, Diseases, Health Care Workforce, Health Services, Coverage, and Access, Quality and Patient Safety
Activity: National Cancer Policy Forum
Board: Board on Health Care Services

On October 25, 2010, the National Cancer Policy Forum hosted the National Cancer Policy Summit. The Summit convened key thought leaders in the cancer community to identify and discuss the most pressing policy issues in cancer research and cancer care. Discussions between invited panelists and Forum members guided the Forum’s strategic planning and ensured that NCPF activities are responsive to priorities in the cancer community.

In addition to the invited panelists, the National Cancer Policy Summit was open to members of the public. All stakeholders were welcomed and encouraged to submit their input to the Forum in writing. 

Confirmed Speakers
•    Kirsten Anderson, Aetna
•    Rachel Ballard-Barbash, National Cancer Institute
•    Bruce Chabner, Dana-Farber/Harvard Cancer Center
•    William Dalton, American Association for Cancer Research 
•    Steve Miller, National Patient Advocate Foundation
•    Kay Dickersin, Johns Hopkins University
•    Lloyd Everson, US Oncology
•    Katie Horton, George Washington University
•    Allen Lichter, American Society of Clinical Oncology
•    Mary McCabe, Memorial Sloan Kettering Cancer Center
•    Diane Meier, Mount Sinai School of Medicine
•    Danny McGoldrick, Campaign for Tobacco-Free Kids
•    Richard Pazdur, Food and Drug Administration
•    Marcus Plescia, Centers for Disease Control and Prevention
•    Mace Rothenberg, Pfizer
•    John Seffrin, American Cancer Society
•    Ellen Sigal, Friends of Cancer Research
•    Peter Ubel, Duke University
•    Harold Varmus, National Cancer Institute
•    Alan Weil, National Academy for State Health Policy


Hal Moses, M.D., Chair
Director Emeritus, Vanderbilt-Ingram Cancer Center

Fred Appelbaum, M.D.
Director, Clinical Research Division, Fred Hutchinson Cancer Research Center

Peter B. Bach, M.D., M.A.P.P.
Associate Attending Physician, Memorial Sloan-Kettering Cancer Center

Edward J. Benz, Jr., M.D.
President & CEO, Dana Farber Cancer Institute, Professor of Medicine and of Pediatrics and of Pathology, Harvard Medical School

Thomas G. Burish, Ph.D.
Past-Chair, American Cancer Society, Board of Directors
Provost, Notre Dame University

Michael A. Caligiuri, M.D.  
Director, The Ohio State University Comprehensive Cancer Center
Chief Executive Officer, James Cancer Hospital and Solove Research Institute

Michaele Chamblee Christian, M.D.
Retired, Division of Cancer Treatment and Diagnosis, National Cancer Institute

Robert Erwin, M.S.
President, Marti Nelson Cancer Foundation

Betty R. Ferrell, Ph.D., R.N., F.A.A.N.
Research Scientist, City of Hope National Medical Center

Joseph F. Fraumeni, Jr., M.D.
Director, Division of Cancer Epidemiology and Genetics
National Cancer Institute

Patricia A. Ganz, M.D.
Professor, UCLA Schools of Medicine & Public Health
Jonsson Comprehensive Cancer Center

Roy S. Herbst, M.D., Ph.D.
Chief, Thoracic/Head & Neck Medical Oncology
M.D. Anderson Cancer Center

Thomas J. Kean, M.P.H.
Executive Director

Douglas R. Lowy, M.D.
Laboratory Chief and Principal Investigator, Signaling and Oncogenesis Section
National Cancer Institute

Martin J. Murphy, Ph.D., DMedSc
Chief Executive Officer, CEO Roundtable on Cancer

Brenda Nevidjon, MSN, RN, FAAN
Immediate Past-President, Oncology Nursing Society, Clinical Professor, Specialty Director, Nursing & Healthcare Leadership
Duke University School of Nursing

David R. Parkinson, M.D.
President and CEO, Oncology Research and Development
Nodality, Inc.

Scott Ramsey, M.D., Ph.D.
Full Member, Cancer Prevention Program, Division of Public Health Science
Fred Hutchinson Cancer Research Center

Lisa C. Richardson, M.D., MPH
Associate Director for Science, Division of Cancer Prevention and Control
Centers for Disease Control and Prevention

John Wagner, M.D., Ph.D.
Full Member; Executive Director, Clinical Pharmacology
Merck and Company, Inc.

Upcoming Meetings for this Activity

Previous Meetings for this Activity

Also of Interest